Status:
UNKNOWN
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
Lead Sponsor:
Charles University, Czech Republic
Collaborating Sponsors:
AstraZeneca
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.
Detailed Description
Patients will be randomly assigned in 1:1 ratio either to candesartan (target dose 32 mg once daily) or matching placebo. The initial dose of the study drug will be 8 mg once daily. Study drug dose wi...
Eligibility Criteria
Inclusion
- HCM defined on the basis of echocardiographic criteria showing a nondilated, hypertrophied left ventricle (any wall thickness \> 15 mm) in the absence of known causes of LV hypertrophy hypertension or valvular disease
Exclusion
- Hypertrophic obstructive cardiomyopathy defined as presence of resting gradient in left ventricular outflow tract ³30 mmHg or in righ ventricular outflow tract ³15 mmHg at Doppler echocardiography;
- Atrial fibrillation;
- Treatment with ACE inhibitors or AT1-R antagonists any time in the past;
- Contraindications to AT1-R antagonists;
- Coronary artery disease, renal failure, hepatic disorders or serious intercurrent illness limiting survival; and
- Poor echocardiographic image quality.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00430833
Last Update
February 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiocenter, Third Faculty of Medicine, Charles University
Prague, Czechia, 10034